Ph3 study to compare the efficacy and safety of sacituzumab in subjects with endometrial cancer
Phase III Clinical Trial
MK2870-033: A Phase 3 Randomized Open-label Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT MK-2870) in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)